135 related articles for article (PubMed ID: 37914595)
1. Benefit of Adjuvant Chemotherapy for Patients Older Than 75 Years With Completely Resected p-Stage II-IIIA Non-Small-Cell Lung Cancer: A Retrospective Cohort Study Using Japanese Nationwide Real-World Data.
Adachi H; Morohoshi T; Shintani Y; Okami J; Ito H; Ohtsuka T; Mori T; Watanabe SI; Chida M; Endo S; Nakanishi R; Kadokura M; Suzuki H; Miyaoka E; Yoshino I; Date H;
Clin Lung Cancer; 2024 Jan; 25(1):61-71.e1. PubMed ID: 37914595
[TBL] [Abstract][Full Text] [Related]
2. Is adjuvant chemotherapy for completely resected p-stage IA (>2 cm) and stage IB non-small-cell lung cancer beneficial for elderly patients? A large, retrospective cohort study based on real-world data from Japan.
Adachi H; Saito A; Shintani Y; Okami J; Ito H; Ohtsuka T; Mori T; Watanabe SI; Chida M; Endo S; Nakanishi R; Kadokura M; Suzuki H; Miyaoka E; Yoshino I; Date H; Japanese Joint Committee Of Lung Cancer Registry
Jpn J Clin Oncol; 2023 Dec; 53(12):1191-1200. PubMed ID: 37626449
[TBL] [Abstract][Full Text] [Related]
3. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
[TBL] [Abstract][Full Text] [Related]
5. Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101).
Yamaguchi M; Tada H; Mitsudomi T; Seto T; Yokoi K; Katakami N; Nakagawa K; Oda M; Ohta M; Sawa T; Yamashita M; Iked N; Saka H; Higashiyama M; Nomori H; Semba H; Negoro S; Chiba Y; Shimokawa M; Fukuoka M; Nakanishi Y;
Int J Clin Oncol; 2021 Dec; 26(12):2216-2223. PubMed ID: 34463869
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ; Wang Q; Mao WM; Xu ST; Wu L; Shen Y; Liu YY; Chen C; Cheng Y; Xu L; Wang J; Fei K; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Yang XN; Zhou Q; Wu YL;
Lancet Oncol; 2018 Jan; 19(1):139-148. PubMed ID: 29174310
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant chemotherapy for completely resected non-small-cell lung cancer.
Suehisa H; Toyooka S
Acta Med Okayama; 2009 Oct; 63(5):223-30. PubMed ID: 19893597
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
[TBL] [Abstract][Full Text] [Related]
9. Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer.
Nakagawa K; Tada H; Akashi A; Yasumitsu T; Iuchi K; Taki T; Kodama K;
Br J Cancer; 2006 Oct; 95(7):817-21. PubMed ID: 16969350
[TBL] [Abstract][Full Text] [Related]
10. Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based study.
Lin ZZ; Shau WY; Shao YY; Yang YY; Kuo RN; Yang JC; Lai MS
Oncologist; 2012; 17(10):1294-302. PubMed ID: 22826374
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Felip E; Altorki N; Zhou C; Csőszi T; Vynnychenko I; Goloborodko O; Luft A; Akopov A; Martinez-Marti A; Kenmotsu H; Chen YM; Chella A; Sugawara S; Voong D; Wu F; Yi J; Deng Y; McCleland M; Bennett E; Gitlitz B; Wakelee H;
Lancet; 2021 Oct; 398(10308):1344-1357. PubMed ID: 34555333
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010).
Kenmotsu H; Sugawara S; Watanabe Y; Saito H; Okada M; Chen-Yoshikawa TF; Ohe Y; Nishio W; Nakagawa S; Nagao H
Cancer Sci; 2022 Dec; 113(12):4327-4338. PubMed ID: 36062851
[TBL] [Abstract][Full Text] [Related]
13. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.
Tsuboi M; Ohira T; Saji H; Miyajima K; Kajiwara N; Uchida O; Usuda J; Kato H
Ann Thorac Cardiovasc Surg; 2007 Apr; 13(2):73-7. PubMed ID: 17505412
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
[TBL] [Abstract][Full Text] [Related]
15. Oral fluorouracil vs vinorelbine plus cisplatin as adjuvant chemotherapy for stage II-IIIA non-small cell lung cancer: Propensity score-matched and instrumental variable analyses.
Urushiyama H; Jo T; Yasunaga H; Michihata N; Matsui H; Hasegawa W; Takeshima H; Sakamoto Y; Hiraishi Y; Mitani A; Fushimi K; Nagase T; Yamauchi Y
Cancer Med; 2018 Oct; 7(10):4863-4869. PubMed ID: 30151905
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.
He J; Shen J; Yang C; Jiang L; Liang W; Shi X; Xu X; He J
Medicine (Baltimore); 2015 Jun; 94(22):e903. PubMed ID: 26039122
[TBL] [Abstract][Full Text] [Related]
17. Oral uracil-tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early-stage non-small cell lung cancer patients.
Liang SK; Wu CW; Chang CI; Keng LT; Lee MR; Wang JY; Ko JC; Liao WY; Chen KY; Ho CC; Shih JY; Yu CJ
Cancer Med; 2023 Sep; 12(17):17993-18004. PubMed ID: 37559409
[TBL] [Abstract][Full Text] [Related]
18. Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC.
Shen ZQ; Feng KP; Fang ZY; Xia T; Pan S; Ding C; Xu C; Ju S; Chen J; Li C; Zhao J
J Cardiothorac Surg; 2024 Jan; 19(1):1. PubMed ID: 38166960
[TBL] [Abstract][Full Text] [Related]
19. A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.
Okamoto T; Yano T; Shimokawa M; Takeo S; Yamazaki K; Sugio K; Takenoyama M; Nagashima A; Tsukamoto S; Hamatake M; Yokoyama H; Ueda H; Motohiro A; Tagawa T; Shoji F; Kometani T; Saito G; Fukuyama Y; Toyokawa G; Osoegawa A; Emi Y; Maehara Y;
Lung Cancer; 2018 Oct; 124():255-259. PubMed ID: 30268470
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.
Custodio Carretero AB; García Sáenz JA; González Larriba JL; Bobokova J; Calles Blanco A; Hernando Trancho F; García Paredes B; Rodríguez Lajusticia L; Díaz-Rubio García E
Clin Transl Oncol; 2008 Sep; 10(9):560-71. PubMed ID: 18796373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]